The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Analyses of tumor microenvironment affecting the survival in patients with ovarian cancer receiving intraperitoneal chemotherapy: Translational research from the phase 3 trial of intraperitoneal therapy for ovarian cancer with carboplatin (TRiPocc).
 
Aiko Ogasawara
No Relationships to Disclose
 
Hirokazu Matsushita
Research Funding - NEC Corporation (Inst)
 
Tuan Zea Tan
No Relationships to Disclose
 
Daisuke Shintani
No Relationships to Disclose
 
Jieru Ye
No Relationships to Disclose
 
Shoji Nagao
Honoraria - AstraZeneca; Chugai Pharma; Mochida Pharmaceutical Co. Ltd.; MSD
Consulting or Advisory Role - AstraZeneca
Research Funding - AstraZeneca (Inst)
 
Yukari Kobayashi
Research Funding - Takara Bio (Inst)
 
Kazuhiro Kakimi
Research Funding - Takara Bio (Inst)
 
Rui Yamaguchi
Honoraria - Novartis
Consulting or Advisory Role - Novartis
 
Kouji Yamamoto
Honoraria - Chugai Pharma; CM Plus; CMIC Co., Ltd.; J-Pharma; Johokiko; Sysmex; Takeda
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Chugai Pharma (Inst); Daiichi Sankyo/UCB Japan (Inst); Kyowa Kirin International (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Keiichi Fujiwara
Honoraria - Chugai Pharma; Daiichi Sankyo; Eisai; Genmab; Taiho Pharmaceutical; Takeda; Zeria Pharmaceutical
Consulting or Advisory Role - Eisai; Genmab; MSD; NanoCarrier; Seagen; Taiho Pharmaceutical; Takeda
Research Funding - AstraZeneca (Inst); Genmab (Inst); MSD (Inst); Regeneron (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - Genmab
 
Ruby Yun-Ju Huang
Employment - Ferring (I)
Stock and Other Ownership Interests - ACT Genomics (I)
Honoraria - GlaxoSmithKline; Illumina
Speakers' Bureau - Illumina
Research Funding - Illumina; Roche
 
David Shao Peng Tan
Stock and Other Ownership Interests - Asian Microbiome Library
Honoraria - AstraZeneca; Bayer; Eisai; Foundation Medicine; Merck; MSD; Roche; Turbine
Consulting or Advisory Role - AstraZeneca; Bayer; Eisai; GlaxoSmithKline; Merck; MSD; Roche
Speakers' Bureau - Roche
Research Funding - AstraZeneca; Bayer; Karyopharm Therapeutics (Inst); Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Bayer; Merck; Novartis; Roche
 
Kosei Hasegawa
Honoraria - AstraZeneca; Chugai Pharma; Daiichi Sankyo; Eisai; Kyowa Kirin; MSD K.K; Sanofi; Takeda
Consulting or Advisory Role - Daiichi Sankyo; Genmab; Kaken Pharmaceutical; MSD K.K; Roche; Sanofi; Takeda
Research Funding - Daiichi Sankyo; Merck; Ono Pharmaceutical